Last reviewed 2026-04-22 · How we verify

Antibiotics first

This is a descriptive name rather than a specific drug entity, referring to a class-based or platform approach to antibiotic development.

This is a descriptive name rather than a specific drug entity, referring to a class-based or platform approach to antibiotic development. Used for Bacterial infections (unspecified).

At a glance

Mechanism of action

Without a specific drug name, brand, or molecular target, 'Antibiotics first' appears to be a research initiative or platform rather than a defined pharmaceutical compound. It likely represents a development strategy prioritizing antibiotic discovery or optimization, possibly from the Chinese University of Hong Kong's research program.

Approved indications

• Bacterial infections (unspecified)

Common side effects

No common side effects on file.

Key clinical trials

• Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
• Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
• Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC (NA)
• Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
• Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
• The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) (NA)
• Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin (NA)
• Eye-Ear Sleep Band for Sleep Quality in Coronary Care Unit (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.